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Abstract During the 1980s and 1990s life expectancy at
birth has risen only slowly in the Netherlands. In 2002,
however, the rise in life expectancy suddenly accelerated.
We studied the possible causes of this remarkable devel-
opment. Mortality data by age, gender and cause of death
were analyzed using life table methods and age-period-
cohort modeling. Trends in determinants of mortality
(including health care delivery) were compared with trends
in mortality. Two-thirds of the increase in life expectancy
at birth since 2002 were due to declines in mortality among
those aged 65 and over. Declines in mortality reflected a
period rather than a cohort effect, and were seen for a wide
range of causes of death. Favorable changes in mortality
determinants coinciding with the acceleration of mortality
decline were mainly seen within the health care system.
Health care expenditure rose rapidly after 2001, and was
accompanied by a sharp rise of specialist visits, drug pre-
scriptions, hospital admissions and surgical procedures
among the elderly. A decline of deaths following non-
treatment decisions suggests a change towards more active
treatment of elderly patients. Our findings are consistent
with the idea that the sharp upturn of life expectancy in the
Netherlands was at least partly due to a sharp increase in
health care for the elderly, and has been facilitated by a
relaxation of budgetary constraints in the health care system.
Keywords Mortality  Life expectancy  Elderly 
Health care
Introduction
The Netherlands has been world champion of life expec-
tancy at birth during some years in the 1930s and 1960s,
but suddenly lost its advantage in the 1980s [1]. During the
1980s and 1990s a complete stagnation of mortality decline
occurred in some age-groups in the Netherlands, while
other high-income countries continued their rapid mortality
declines. This happened both among the very young
(perinatal mortality) and among the very old (80?). Stag-
nation of mortality at both ends of the age-spectrum started
around 1980, and was noted first for perinatal mortality [2,
3] and later for old-age mortality [4–6]. Analyses of cause-
of-death patterns showed that the stagnation of old-age
mortality decline in the Netherlands could partly be
attributed to smoking-related causes of death. The evidence
also showed a contribution of ill-defined causes of death
which are typical for old age (e.g. mental and neurological
disorders) [7].
A previous version of this paper was prepared for the National
Academy of Sciences Panel on Divergent Trends in Life Expectancy
in High-Income Countries [34].
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A stagnation of mortality decline among the elderly has
also been observed in a small number of other countries,
particularly the US and Denmark [8, 9]. Interestingly,
however, progress in mortality decline among the elderly
has resumed in Denmark around 1995 [10], and in the
Netherlands around 2002, while the United States show no
signs of a reversal yet. As Fig. 1 shows, from 2002 to 2008
life expectancy at birth in the Netherlands has increased by
almost 2 years from 76.0 to 78.3 years among men, and
from 80.7 to 82.3 years among women). This paper aims to
assess the possible causes of the reversal from stagnation to
renewed decline of old-age mortality in the Netherlands.
We show that the recent upturn of life expectancy in the
Netherlands can plausibly be ascribed to an expansion of
health care, particularly for the elderly. Our paper therefore
adds to a growing literature on the potential importance of
medical care as a determinant of life expectancy in high-
income countries. This has long been a topic of great
controversy, based on historical analyses which suggest
that other determinants, like increasing prosperity, better
nutrition or public health measures, have been much more
important for the secular decline in mortality [11, 12].
However, recent evidence from a range of countries sug-
gests that medical care is increasingly important for further
gains in survival, after infectious diseases had largely been
eliminated as a cause of death [13–16].
Data and methods
Mortality data were extracted from the national registry kept
at Statistics Netherlands, which is derived from the muni-
cipal population registries which are continuously kept up to
date. Underlying causes of death were coded according to
the International Classification of Diseases (9th and 10th
revisions). In order to calculate age- or cause-specific con-
tributions to gains in life expectancy we calculated the
number of life years that would have been gained if only the
observed age- or cause specific mortality risks would have
changed during the period, keeping all other mortality risks
constant. We also performed an age-period-cohort analysis
to test whether changes in mortality occurring around 2002
were due to cohort- or period-effects [17, 18].
Data on determinants of mortality (sociodemographics,
lifestyle, health status, health care) were extracted from reg-
istrations and surveys kept at Statistics Netherlands (CBS;
data mostly available online at http://statline.cbs.nl/statweb/),
the National Institute for Public Health and the Environment
(RIVM), and the Health Care Insurance Board (CvZ). Age-
adjusted annual percent changes and annual rate changes
were calculated with regression analysis allowing for a
change in trend in 2001, 1 year earlier than the change in
mortality trend. Self-reported data on lifestyle, health status
and health care utilization came from the national living
conditions survey (POLS) which is held on a continuous basis
among representative samples of the non-institutionalized
population of the Netherlands. Because of substantial chan-
ges in the questionnaire only data from 2001 onwards could
be used. Data on drug prescriptions came from the national
registration of drugs reimbursed by public and private health
care insurers (GIP database). Data on hospital admissions,
clinical incidence (i.e., incidence of a first clinical episode for
a particular disease) and hospital procedures came from the
national registration of hospital admissions (LMR) which
includes clinical as well as day care admissions. Data on
health care expenditure came from detailed cost-of-illness
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Fig. 1 Life expectancy at birth, by gender, the Netherlands, 1950–2008. Source: Statistics Netherlands (http://statline.cbs.nl/statweb/)
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studies for the years 1994, 1999, 2003, and 2007 which have
been performed by the National Institute for Public Health
and the Environment (RIVM) [19]. These studies are based
on a wide range of administrative data covering all health care
sectors, and data were re-analyzed to derive age- and gender-
specific patterns of health care expenditure. Data on end-of-
life decisions came from a series of surveys among physicians
who acted as cause-of-death certifiers for a representative
sample of deaths (excluding acute deaths) in 1990, 1995,
2001 and 2005 [20].
Results
As Table 1 shows, around two-thirds of the increase in life
expectancy after 2002 resulted from declines in mortality
among those aged 65 years and older, both in men and
women. As compared to the period before 2002, an
acceleration of mortality decline can be observed in nearly
all age-groups, but was particularly noteworthy among the
elderly. This acceleration occurred simultaneously in many
age-groups, suggesting a period- rather than a cohort-
effect. We tested this hypothesis in a formal age-period-
cohort analysis which shows that a model allowing for a
period effect is much better in explaining the mortality
trend data than a model allowing for a birth-cohort effect.
For both men and women the model estimate of the point in
time at which a period change occurred was between 2001
and 2002 (see Web appendix 1).
Many cause-of-death groups contributed to the rise in
life expectancy after 2002. Cardiovascular disease is the
main contributor (life-years gained between 2002 and
2008: 0.82 years in men, 0.65 years in women), followed
by symptoms and ill-defined conditions (0.16 years in men,
0.18 years in women) and by respiratory conditions
(0.16 years in men, 0.05 years in women) (see Web
appendix 2). For several specific causes of death clear
accelerations of mortality decline, or even reversals from
increasing to declining trends occurred in or around 2002
(Fig. 2). This includes diabetes, stroke, mental disorders
(mainly vascular and non-specified dementia), pneumonia,
and symptoms and ill-defined conditions. While the stag-
nation of old-age mortality during the 1980s and 1990s was
partly due to smoking-related causes, the continuing
increase in lung cancer mortality among women suggests
that the decline of old-age mortality after 2002 was not.
We reviewed trends in a wide range of determinants of
mortality, comparing developments before and after 2001
where possible. After 2001 there were very few favorable
trends in sociodemographics, lifestyle or health status
among the elderly. Actually, many trends were unfavorable:
the age-adjusted prevalence of smoking (women only),
obesity, diabetes and hypertension increased, as well as the
incidence of acute myocardial infarction and stroke (see
Web appendix 3). However, we did find favorable changes
in health care delivery (Table 2). There were substantial
increases in the age-adjusted percentage of elderly visiting a
medical specialist, using prescribed drugs, being admitted to
hospital, and undergoing surgery. This included treatment
for cardiovascular conditions: the age-adjusted percentage
of elderly receiving lipid- or blood pressure-lowering drugs
or undergoing surgical procedures for cardiovascular prob-
lems increased much more rapidly between 2001 and 2007
than it did between 1995 and 2001. The most spectacular
increases were seen for lipid-lowering drugs (mostly stat-
ins): for example, among men and women aged 80–84 the
proportion of persons on lipid-lowering drugs increased
from 7.5% in 2000 to 32.8% in 2008.
Hospital admission rates among the elderly rose only
slowly during the 1990s, but the rate of increase suddenly
Table 1 Contribution of age-
specific mortality declines (in
years and as a percentage of
total) to increases in life
expectancy at birth, by gender,
1995–2002 and 2002–2008
Source: authors’ analyses of
data available at Statistics
Netherlands
Men Women
1995–2002 (%) 2002–2008 (%) 1995–2002 (%) 2002–2008 (%)
0 0.04 (3) 0.05 (2) -0.01 (-3) 0.05 (3)
1–14 0.08 (6) 0.05 (2) 0.06 (18) 0.02 (1)
15–29 0.04 (3) 0.09 (4) 0.02 (6) 0.07 (5)
30–49 0.15 (11) 0.19 (9) 0.03 (9) 0.17 (12)
50–64 0.34 (24) 0.37 (17) 0.02 (6) 0.20 (14)
65–69 0.24 (17) 0.21 (10) 0.11 (33) 0.10 (7)
70–74 0.20 (14) 0.49 (23) 0.01 (3) 0.18 (12)
75–79 0.18 (13) 0.37 (17) 0.06 (18) 0.19 (13)
80–84 0.09 (6) 0.18 (8) 0.02 (6) 0.18 (12)
85–89 0.02 (1) 0.10 (5) 0.02 (6) 0.18 (12)
90–94 0.01 (1) 0.05 (2) -0.01 (-3) 0.09 (6)
95? 0.01 (1) 0.01 (0) 0.00 (0) 0.03 (2)
Total 1.40 (100) 2.17 (100) 0.33 (100) 1.46 (100)
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accelerated in 2001 (Fig. 3). This acceleration occurred for
many disease groups, including cancer, diseases of the ner-
vous system, cardiovascular diseases, and injuries (results
not shown). Health care expenditure per head of population
rose only modestly between 1994 and 1999, but rose rapidly
between 1999 and 2003 (Fig. 4). The increase was largest
among the elderly, due to a rapid expansion of hospital care
and care for the elderly (residential care and home care).
Survey data among Dutch physicians show that the fre-
quency of end-of-life decisions which hasten death (eutha-
nasia, alleviation of symptoms with high doses of morphine,
and withholding or withdrawing life-prolonging treatment)
b
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Fig. 2 Selected cause-specific mortality trends, by age, women, the Netherlands, 1990–2008 (mortality levels relative to those in 2002,
expressed as a percentage (2002 = 100%)). Source: authors’ analyses of data available at Statistics Netherlands
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rose slightly during the 1990s. Between 2001 and 2005,
however, there was a strong decline in the proportion of
deaths in which life-prolonging treatment had been withheld
or withdrawn (Table 3). This decline was particularly
noteworthy among the elderly and for treatment with anti-
biotics, and is seen in all causes of death (results not shown).
Discussion
We found that two-thirds of the increase in life expectancy
at birth since 2002 were due to declines in mortality among
those aged 65 and over, and that these declines reflect a
period rather than a cohort effect, suggesting that the causal
c
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factor or factors started to act with a short rather than with
a long delay. Striking accelerations or even reversals of
mortality trends occurred for various causes of death, many
of which are typical for old-age such as stroke, pneumonia,
dementia, and symptoms and ill-defined conditions.
Favorable changes in mortality determinants coinciding
with the acceleration of mortality decline mainly occurred
within the health care system. Health care expenditure rose
rapidly after 2001, and was accompanied by a sharp rise of
elderly persons seeing a specialist, using prescribed drugs,
e
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being admitted to hospital, and undergoing surgical pro-
cedures. This included sharp rises in drug and surgical
treatment for cardiovascular conditions, the cause-of-death
group contributing most to the rise of life expectancy. A
decline of deaths following non-treatment decisions is
consistent with a change in physicians’ attitudes towards
more active, life-prolonging treatment of elderly patients.
The results suggest that the sharp upturn of life expec-
tancy in the Netherlands was at least partly due to a sharp
increase in health care for the elderly, and has been
g
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facilitated by a relaxation of budgetary constraints in the
health care system. That a more liberal administration to
elderly patients of life-prolonging treatments has played a
role in mortality decline is consistent with the decline in
one-year case fatality among hospital patients which has
been observed in the Netherlands [21]. Between 2001 and
2005, mortality within 1 year after hospital admission
declined for many conditions. Among those aged 80 years
and over, the average decline (for all conditions combined)
was about 14% (from 26 to 22%). This decline occurred for
many conditions, including ischemic heart disease (where
one-year case fatality declined from 34 to 28%) and stroke
(where one-year case fatality declined from 52 to 45%)
[21]. Because there was a simultaneous increase in the
hospital admission rate (Fig. 3), the decline in case fatality
may also, at least partly, reflect a shift towards less severely
ill patients. In the case of stroke, a plausible explanation for
the decline of the one-year case fatality rate (and for the
acceleration of mortality) is more rapid and more aggres-
sive treatment for stroke in specialized stroke units, which
were implemented on a large scale from about 2000
onwards [22].
In the case of pneumonia, dementia, and symptoms and
ill-defined conditions, a more active approach towards the
treatment of seriously ill elderly patients may have played
a role too. Changes in mortality from these conditions are
often regarded as indicative of ‘‘artefacts’’ of certification
or coding, but these also reflect changes in physicians’
attitudes. As coding practices within Statistics Netherlands
have not been systematically documented it is difficult to
Table 2 Trends in health care delivery (absolute annual changes in age-standardized rate, with 95% confidence intervals) among those aged 65
and older, by gender, the Netherlands, 1995–2001 and 2001–2007
Unit 1995–2001 2001–2007
Vaccinated against influenza (self-reported) Men & Women % 4.799 (3.125–6.474) 20.530 (-1.807–0.746)
Contact with GP in 1 year (self-reported) Men % 20.653 (-1.179-0.127)
Contact with GP in 1 year (self-reported) Women % -0.256 (-0.662–0.150)
Contact with specialist in 1 year (self-reported) Men % -0.044 (-0.821–0.734)
Contact with specialist in 1 year (self-reported) Women % 1.274 (0.512–2.036)
Use of prescribed drugs (self-reported) Men % 0.846 (0.370–1.322)
Use of prescribed drugs (self-reported) Women % 1.099 (0.648–1.551)
Betablocker prescriptions Men % 1.190 (0.992–1.388) 1.717 (1.519–1.915)
Betablocker prescriptions Women % 0.924 (0.667–1.182) 1.250 (0.993–1.508)
Statin prescriptions Men % 1.959 (1.630–2.287) 3.330 (3.002–3.659)
Statin prescriptions Women % 1.361 (1.014–1.709) 2.384 (2.036–2.731)
Hospital admissions
(including daycare admissions)
Men per 100 py 0.218 (0.088–0.345) 2.409 (2.280–2.538)
Hospital admissions
(including daycare admissions)
Women per 100 py 0.523 (0.423–0.624) 2.363 (2.263–2.462)
All surgical procedures
(including during daycare admission)
Men per 100 py 0.108 (0.032–0.185) 0.578 (0.501–0.654)
All surgical procedures
(including during daycare admission)
Women per 100 py 0.316 (0.256–0.373) 0.592 (0.536–0.649)
Cardiac catheterizations Men per 100 py 0.027 (0.011–0.042) 0.062 (0.046–0.077)
Cardiac catheterizations Women per 100 py 0.015 (0.008–0.021) 0.042 (0.035–0.049)
Pacemaker implantations Men per 100 py 0.011 (0.007–0.014) 0.014 (0.011–0.017)
Pacemaker implantations Women per 100 py 0.006 (0.003–0.009) 0.011 (0.008–0.013)
Percutaneous transluminal
coronary angioplasties (PTCA)
Men per 100 py 0.101 (0.069–0.132)
Percutaneous transluminal
coronary angioplasties (PTCA)
Women per 100 py 0.048 (0.036–0.060)
Coronary bypass operations Men per 100 py 20.008 (-0.015 to -0.001) 0.002 (-0.005–0.009)
Coronary bypass operations Women per 100 py 20.005 (-0.007 to -0.002) 0.003 (-0.002–0.003)
All data are register-based unless otherwise declared
All data have been directly age-standardized to the 2001 Netherlands population
Figures in bold: 95% confidence intervals of trend estimates do not include 0
Figures in italics: 95% confidence intervals of trend estimates before and after 2001 do not overlap
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exclude changes in coding practice as an explanation. To
the extent that they reflect changes in certification of causes
of death, however, they suggest that physician attitudes
have changed over time. Deaths certified as being caused
by ‘‘pneumonia’’ can also be interpreted as a decision by
the physician not to search for a better diagnosis, or if a
better diagnosis is available not to treat the patient for this
disease, but to let him or her die from what has always been
considered the ‘‘old man’s friend’’ [23]. The same applies
to dementia, which as long as its complications are ade-
quately treated will in itself not lead to death. If a death is
being certified as caused by dementia, the physician has
probably decided that further treatment is useless. For this
very reason, dementia has long not been accepted as a
possible ‘‘underlying’’ cause of death [24].
That the upturn of life expectancy may at least partly be
due to a more liberal administration to elderly patients of
life-prolonging treatments is also consistent with the results
of end-of-life surveys in the Netherlands. These surveys
show a strong decline in the proportion of deaths among
the elderly in which life-prolonging treatment had been
withheld or withdrawn (Table 3). For example, less with-
holding of treatment with antibiotics may have contributed
to the reversal in the trend of mortality from pneumonia
(Fig. 2). In these surveys, physicians were asked to esti-
mate the amount of time by which life was shortened, and
this was generally small but largest for withholding or
withdrawing of life-prolonging treatment [20]. The decline
of the latter practice may therefore also have had a direct
effect on survival rates in the population. An international
survey has shown that Dutch physicians used to have
higher frequencies of making end-of-life decisions than
their colleagues in other European countries [25, 26], and
we have shown elsewhere that the proportion of deaths
with one of these end-of-life decisions was positively
correlated with mortality rates among the elderly [27].
More health care may not only have reduced old-age
mortality through more in-hospital treatment and/or more
active treatment of severely ill patients, but also through
more liberal administration in an outpatient setting of drugs
which may prevent severe illness. The increase in pre-
scription of lipid- and blood pressure lowering drugs to
elderly people may have contributed to mortality decline
because both types of drugs have been shown to reduce
mortality, and to do so within a few years after start of
treatment [28, 29]. Liberalization of preventive drug
treatment can be traced in professional guidelines, which
have gradually relaxed or abolished age-limits in the pre-
scription of these drugs. For example, in 1999, the guide-
line of the Dutch Society of General Practice (NHG) for
prescribing cholesterol lowering drugs still included an
upper age-limit of 70 years for men and 75 years for
women. In 2006, the new guideline on cardiovascular risk
management no longer had age-limits for cholesterol
lowering or blood pressure lowering drugs [30]. In this
case, the guidelines have apparently formalized changes
which had already started to occur in the practice of health
care.
We believe that the evidence for a contribution of
increased health care delivery to the upturn of life expec-
tancy in the Netherlands is compelling, but acknowledge
that parallel trends in population-wide health care delivery
and mortality indicators do not prove that one has led to the
other. Individual level data, if they can be found, could be
used to check whether the increases in survival really
occurred among people who had received more health care,
e.g. lipid-lowering drugs or PTCAs. The same applies to
international comparisons of trends in determinants and
trends in life expectancy.
The expansion of health care for the elderly coincided
with a clear-cut change in growth of health care expendi-
ture in the Netherlands. Long-term trends in health care
spending in the Netherlands show a very distinct pattern,
characterized by rapid growth in the 1960s and 1970s,
relatively slow growth in the 1980s and 1990s, and rapid
growth again in the first years of the new millennium. In
terms of the volume of care annual growth rates were 4% in
the 1970, 2% in the 1980s, 2% in the 1990s, and almost 6%
in the period 2001–2007. Expressed as a proportion of
Gross National Product, health care expenditure rose from
about 4% in 1960 to about 9% in 1980, remained more or
less stable until the year 2000, and then rapidly increased
again to slightly above 10% in 2008. The annual growth
rate of health care expenditure (in constant prices, i.e.
adjusted for inflation) peaked in 2001, 2002, and 2003. It
was 3.1% in 1999, 3.6% in 2000, 5.4% in 2001, 4.4% in
2002, 4.3% in 2003, 3.2% in 2004, 2.9% in 2005, 2.6% in
2006, and 3.1% in 2007 [31].
Table 3 Proportion of deaths (percentage and 95% confidence intervals) in which life-prolonging treatment has been withheld or withdrawn, by
age, the Netherlands, 1990–2005
Age-group 1990 1995 2001 2005
0–64 13 (11–15) 14 (12–16) 16 (14–18) 13 (12–15)
65–79 15 (14–17) 17 (15–19) 19 (17–21) 14 (13–16)
80 and over 23 (21–25) 26 (24–28) 23 (21–25) 17 (16–19)
Source: authors’ calculations of data collected in four national surveys of end-of-life decisions (for details on design of study see [20])
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The sudden rise in health care expenditure after 2001
was due to a conscious decision by the Dutch government
to relax the budgetary restraints of the 1980s and 1990s.
During these two decades the Dutch government had
successfully limited the growth of health care expenditure,
first by a strict regulation of supply (hospital beds,
expensive equipment, specialized personnel, …), then by
imposing budget constraints for in-patient care. As a result,
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Fig. 3 Hospital admission rates by age, the Netherlands, 1993–2007. Source: Statistics Netherlands (http://statline.cbs.nl/statweb/)
Fig. 4 Health care expenditure
by age, women, the
Netherlands, in 1997 Euros per
person, 1994–2007. Source:
data collected and analyzed by
the National Institute for Public
Health and the Environment
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the proportion of GDP spent on health care in the Neth-
erlands rose less than in many other high-income countries.
As shown in Table 4, health care expenditure rose more
rapidly during the 1980s and 1990s in Belgium, France,
Germany, Switzerland, the United Kingdom and the United
States. The only other countries with similar stagnation in
the proportion of GDP spent on health care were Denmark
(which also experienced a stagnation in life expectancy)
and Sweden [32]. By 2001 public dissatisfaction with
waiting lists and other problems of access to the health care
system had become so wide-spread in the Netherlands that
the government decided to remove budgetary restraints. In
the plan ‘‘Zorg verzekerd’’ (‘‘Care insured (or ensured)’’)
the government promised that all necessary treatments
would be eligible for reimbursement [33]. As a result,
health care costs rose sharply, until new but less tight
restrictions were re-imposed around 2004.
It is difficult to say whether the relaxation of budgetary
constraints directly caused the expansion of health care, or
only facilitated a change that had its own momentum.
Conceivably, these simultaneous changes in health care
delivery and health care financing reflected a change
towards less complacent attitudes to health care which
were shared by both professionals and policy-makers. The
early years of the new millennium were not only a period
of rapid economic growth which made budgetary con-
straints less acceptable, but also of profound changes in
public opinion, accelerated by the murder of Dutch poli-
tician Pim Fortuyn in 2001. Increased responsiveness of the
health care system to consumer needs therefore may have
been part of broader cultural changes as well.
In conclusion, although important questions remain a
plausible hypothesis for explaining the sudden reversal of
old-age mortality trends in the Netherlands is more health
care for the elderly, which was at least facilitated by a
sudden relaxation of budgetary restraints.
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